News Releases

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/29/13 -- Insmed Incorporated (NASDAQ: INSM) a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/22/13 -- Insmed Incorporated (NASDAQ: INSM) today announced the closing of a $71.8 million underwritten public offering of 6,900,000 shares of common...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/17/13 -- Insmed Incorporated (NASDAQ: INSM) ("Insmed") announced today that it priced an offering of 6.0 million shares of its common stock at a price...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/15/13 -- Insmed Incorporated (NASDAQ: INSM) ("Insmed") announced today that it is offering $60 million of its common stock in a proposed underwritten...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 07/08/13 -- Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)-- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 06/28/13 -- Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 06/28/13 -- Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/14/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/13/13 -- Insmed Incorporated (NASDAQ: INSM) ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/10/13 -- Insmed Incorporated (NASDAQ: INSM) ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/07/13 -- Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/01/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...

MONMOUTH JUNCTION, NJ -- (Marketwired) -- 04/18/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...

MONMOUTH JUNCTION, NJ -- (Marketwire) -- 04/01/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...

ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/28/13 -- Insmed Incorporated (NASDAQ: INSM), a...

MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/27/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...

MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/18/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...

MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/11/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...

MONMOUTH JUNCTION, NJ -- (Marketwire) -- 02/26/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...

MONMOUTH JUNCTION, NJ -- (Marketwire) -- 02/06/13 -- Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for patients with high unmet need who are battling...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's CLinical...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that Will Lewis, President and Chief...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the appointment of Andrew Drechsler...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, will host a...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today announced that

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the election of Al Altomari to its...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the U.S. Patent and Trademark...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's Executive Vice...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, will host a conference call on Tuesday, August 7th,...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that Renu Gupta, M.D., Executive...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that it has entered into a loan...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company's U.S. phase 2 clinical study of ARIKACE® (liposomal...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today provided a corporate update, including the Company's current strategic development priorities for ARIKACE® (liposomal...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the appointments of Donald J. Hayden, Jr. as Executive Chairman of the Company's Board of Directors, and Randall...

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2012. Key Recent Highlights: U.S. Food and Drug Administration (FDA)...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE®...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 8th, 2012, at 8:30 AM ET, to discuss its financial results for the first quarter of...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced the initiation of the Company's CLinical Evaluation of ARIKACE phase 3 study (CLEAR-108) of ARIKACE® (liposomal...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the fourth quarter and fiscal year ended December 31, 2011. Key Recent Highlights: Clinical hold...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, March 13th, 2012, at 8:30 AM ET, to discuss its financial results for the fourth quarter...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company is proceeding with a phase 2 clinical trial of ARIKACE® (liposomal amikacin for inhalation) in...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE®...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the Lazard Capital...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended September 30, 2011. Key Recent Highlights: FDA...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, November 8th, 2011, at 8:30 AM ET, to discuss its financial results for the third...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that it is continuing the...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the Sixth Annual...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President and CEO of Insmed, will be presenting a corporate overview at the 2011 Wedbush...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the second quarter and six-months ended June 30, 2011. Key Recent Highlights: Announced positive...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that the agency has placed a clinical...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Monday, August 8th, 2011, at 8:30 AM ET, to discuss its financial results for the second quarter...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that Andrea ("Andi") Holtzman Drucker, J.D. has been appointed to the newly created position of Senior Vice...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has been added to the Russell 3000® Index following Russell Investments' reconstitution of its...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2011. Key Recent Highlights: Received Food and Drug Administration...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, will host a conference call on Tuesday, May 10th, 2011, at 8:30 AM ET, to discuss its financial results for the first quarter of...

Insmed Incorporated (Nasdaq CM: INSMD), a biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock Market that it has regained compliance with the minimum...

Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of...

Insmed Inc. (Nasdaq CM: INSMD), a biopharmaceutical company, today reported results for the fourth quarter and full-year ended December 31, 2010. Key Recent Highlights: Filed Investigational New...

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that the Pediatric Committee of the European Medicines Agency (EMA) has issued a positive opinion on the Company's...

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that the one-for-10 reverse stock split of Insmed's Common Stock became effective as of 5:00 PM EST, on March 2,...

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that Insmed's shareholders approved the proposal relating to the conversion of Insmed's Series B Conditional...

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that Timothy Whitten, President & CEO of Insmed, will participate on the Phase III and Beyond panel as part of the 2011

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, announced today that it will host a conference call on Thursday, March 10th, 2011, at 8:30 AM EST, to discuss its financial results...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that it had received a letter, dated December 16, 2010, from The NASDAQ Stock Market, notifying Insmed that it...

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, announced today that it has entered into a business combination, effective immediately, with Transave, Inc., a privately-held,...

Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the third quarter and nine-months ended September 30, 2010. Total revenues for the third quarter ended September...

RICHMOND, Va., Oct 26, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Wednesday,...

RICHMOND, Va., Aug 04, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the second quarter and six-months ended June...

RICHMOND, Va., July 28, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Wednesday,...

RICHMOND, Va., June 21, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Incorporated (NASDAQ CM: INSM), a biopharmaceutical company, today announced that on June 18, 2010 it received a NASDAQ...

RICHMOND, Va., May 6, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq CM: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31, 2010....

RICHMOND, Va., April 22, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it will host a conference call on Thursday,...

RICHMOND, Va., March 22, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that Nicholas A. LaBella Jr., MS, RPh, has joined...

RICHMOND, Va., March 15, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the fourth quarter and full-year ended...

RICHMOND, Va., March 4, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company, today announced that it has received notification from The...

RICHMOND, Va., March 3, 2010 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Monday, March...

RICHMOND, Va., Nov 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the third quarter and nine-months...

RICHMOND, Va., Oct 22, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on...

RICHMOND, Va., Sept 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that on September 15, 2009 it...

RICHMOND, Va., Aug 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the second quarter and six-months...

RICHMOND, Va., July 31, 2009 /PRNewswire via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it will host a conference call on Thursday,...

RICHMOND, Va., July 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that, effective immediately, the Company...

RICHMOND, Va., June 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it has been added to the Russell 3000...

RICHMOND, Va., June 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced results from its exploratory U.S. Phase II...

RICHMOND, Va., June 15, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that Geoffrey Allan, Ph.D. has resigned as...

RICHMOND, Va., May 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today reported results for the first quarter ended March 31,...

RICHMOND, Va., May 5, 2009 /PRNewswire via COMTEX News Network -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced that it has received notification from The NASDAQ Stock...

RICHMOND, Va., April 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it will host a conference call on...

RICHMOND, Va., April 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it will host a conference call on...

RICHMOND, Va., March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, announced today that it has successfully closed the sale of...

RICHMOND, Va., March 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- INSMED WILL CONTINUE TO MANAGE ALS EAP IN ITALY AND ALL IPLEX(TM) INITIATIVES IN THE U.S. IDIS WILL HAVE...